newsfilter
← Latest News
GlobeNewswire·

Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial

NX-13 Demonstrated Favorable Safety and Tolerability Profile Across Range of Once-Daily Doses Results Indicate Promising Early Signals Regarding the Efficacy of NX-13 Phase 2 Proof of Concept Clinical Trial in Ulcerative Colitis Planned NEW YORK